Day: April 5, 2025
PASCAGOULA, Miss., April 05, 2025 (GLOBE NEWSWIRE) — HII’s (NYSE: HII) Ingalls Shipbuilding division welcomed more than 80 Scouts from Mississippi, Alabama, and as far north as Kentucky and Tennessee for its second annual Scouts merit badge day at the Ingalls Maritime Training Academy. The event, designed to inspire and support the next generation of leaders, provided Scouts the opportunity to explore shipbuilding career interests and gain hands-on experience in various technical fields found at Ingalls.
“We are grateful to host this event again at Ingalls and to see so many returning and new Scouts this year,” Ingalls Shipbuilding Community Relations Manager Lisa Bradley said. “Scouting builds character, leadership, and technical skills that align closely with what we value in our Ingalls workforce and it’s an honor to be able...
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease
Written by Customer Service on . Posted in Public Companies.
ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference
Prespecified delayed-start analysis indicate disease-modifying effect of oral blarcamesine and importance of early and continued long-term treatment of chronic Alzheimer’s disease
Blarcamesine exhibited a favorable safety profile with no treatment-related deaths
NEW YORK, April 05, 2025 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that over three years of continuous treatment with blarcamesine (ANAVEX®2-73)...
GOGL – Appointment of CEO and CFO
Written by Customer Service on . Posted in Public Companies.
The Board of Golden Ocean Group Ltd. (“Golden Ocean” or the “Company”) is pleased to announce the appointment of Mr. Peder Simonsen as the Chief Executive Officer of Golden Ocean Management AS. Mr. Simonsen currently serves as the Interim Chief Executive Officer and Chief Financial Officer of Golden Ocean Management AS.
Further, the Company is pleased to announce the appointment of Ms. Randi Navdal Bekkelund as Chief Financial Officer of Golden Ocean Management. Ms. Bekkelund currently serves as the Chief Financial Officer of Avance Gas Holding Ltd. Ms. Bekkelund will commence her new role on June 1, 2025.
April 5, 2025
The Board of DirectorsGolden Ocean Group Ltd.Hamilton, Bermuda
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress
Written by Customer Service on . Posted in Public Companies.
New Data Demonstrate Proportion of Corrected M-AAT Reached a Mean of 91% of Total AAT in Circulation at Day 28 Following BEAM-302 Treatment in 60 mg Cohort (n=3)
Mean Decrease of 79% in Mutant Z-AAT Observed at Day 28 in 60 mg Cohort (n=3)
Fourth Cohort Evaluating 75 mg of BEAM-302 Initiated, with Updated Data from Part A of the Phase 1/2 Trial Expected to be Presented at a Medical Conference in Second Half of 2025
CAMBRIDGE, Mass., April 05, 2025 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD) at the 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress, taking place April 4-5,...